Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study

Dizeyi, Nishtman LU ; Mattisson, Ingrid Yao LU ; Ramnemark, Lena ; Grabe, Magnus LU and Abrahamsson, Per Anders LU (2019) In Phytotherapy Research 33(9). p.2457-2464
Abstract

The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the... (More)

The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p <.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p <.001) and stromal cells (p <.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
benign prostatic hyperplasia, Cernitin®, cytokines, prostatitis
in
Phytotherapy Research
volume
33
issue
9
pages
2457 - 2464
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85069887947
  • pmid:31342610
ISSN
0951-418X
DOI
10.1002/ptr.6438
language
English
LU publication?
yes
id
3da7974e-bd25-4af8-9003-7460845d9b40
date added to LUP
2019-08-28 16:13:39
date last changed
2024-02-15 19:11:15
@article{3da7974e-bd25-4af8-9003-7460845d9b40,
  abstract     = {{<p>The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non-bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH-1 and WPMY-1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. Results revealed that Cernitin® upregulated antiinflammatory cytokine interleukin (IL)-10 and its receptors IL-10RA and IL-10B in addition to the upregulation of tumour necrosis factor-related apoptosis-inducing ligand in hPBMC. Interestingly, the levels of proinflammatory cytokines IL-6 and IL-8 were also increased. Furthermore, Cernitin® had significantly increased the level of IL-10 in BPH-1 and WPMY-1 cells. The level of IL-6 was also significantly increased in these cells although both T60 and GBX inhibited STAT-3 phosphorylation. Moreover, Cernitin® formulas had significantly reduced androgen receptor and prostate-specific antigen protein expression in stromal cells (p &lt;.05). Treatment with GBX and T60 had significantly inhibited proliferation of BPH (p &lt;.001) and stromal cells (p &lt;.05), in a dose-dependent manner. Taken together, treatment with Cernitin® showed to regulate cytokines level in both prostatic cell lines and hPBMCs and it was associated with decreased androgen receptor and prostate-specific antigen levels WPMY-1 cells.</p>}},
  author       = {{Dizeyi, Nishtman and Mattisson, Ingrid Yao and Ramnemark, Lena and Grabe, Magnus and Abrahamsson, Per Anders}},
  issn         = {{0951-418X}},
  keywords     = {{benign prostatic hyperplasia; Cernitin®; cytokines; prostatitis}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{9}},
  pages        = {{2457--2464}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Phytotherapy Research}},
  title        = {{The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia : An in vitro study}},
  url          = {{http://dx.doi.org/10.1002/ptr.6438}},
  doi          = {{10.1002/ptr.6438}},
  volume       = {{33}},
  year         = {{2019}},
}